SEMA
20 mg (lyophilized)
CAS #:
910463-68-2
LOT #:
258025
Purity:
99.94%
Endotoxin:
PASS
Cap colour is for illustration purposes only
SEMA
20 mg (lyophilized)
+ $25 flat-rate shipping · free at $300+ · Interac e-Transfer ·
Volume pricing
Orders with confirmed payment before 2 PM EST on business days ship same day
About this compound
SEMA is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) with approximately 94% structural homology to native human GLP-1. It incorporates a C18 fatty diacid chain via a hydrophilic linker at position 26 lysine, enabling strong albumin binding and an extended plasma half-life of approximately 7 days in preclinical models. SEMA activates the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed in the pancreas, central nervous system, gastrointestinal tract, and cardiovascular tissue. Preclinical research has extensively examined SEMA for its effects on glucose homeostasis, appetite regulation, body weight modulation, and metabolic biomarker profiles in multiple animal models.
Storage and handling
Store at -20°C lyophilized, away from moisture and UV light. Keep vials sealed until use. Stable for 2+ years in a non-frost-free freezer.
Preclinical research references
Provided for informational context only. All cited studies involve preclinical or in vitro models. Results do not predict human safety or efficacy. These references do not constitute medical claims.
- Rodent models demonstrated that SEMA administration produced significant reductions in food intake and body weight through GLP-1R-mediated hypothalamic appetite suppression pathways (Christou et al., 2019)
- Diet-induced obese mouse models showed SEMA treatment reduced visceral and subcutaneous adipose tissue mass, improved insulin sensitivity, and normalized fasting glucose compared to vehicle controls (Fonseca et al., 2019)
- Rat pharmacokinetic studies confirmed extended plasma half-life due to albumin binding and reduced renal clearance, supporting extended dosing intervals in preclinical efficacy models (Lau et al., 2015)
- Animal cardiovascular research demonstrated GLP-1R agonism attenuated atherosclerotic plaque progression and reduced inflammatory cytokine expression in aortic tissue of ApoE-deficient mouse models (Nagareddy et al., 2019)
Shipping & returns
1–5 business days (5–7 for BC, NL and remote areas), Canada-wide tracked courier, double tamper-proof packaging.
All sales final. Damaged or incorrect orders must be reported within 24 hours with photos.
Every batch independently tested for purity. COA on file and available before purchase.
FAQ — SEMA
For research use only. Not for human or veterinary administration.